منبع: MarketBeat
خبرگزاری
سهام
اهمیت متوسط
Ocugen Q2 Earnings Call Highlights
Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
نمادهای مرتبط
1
O
OCGN
OCGN
منبع: MarketBeat
مشاهده منبع